1897                      Marcel Mérieux creates the Institut Mérieux, which developed a large range of vaccines and biological products, including reagents. Alain Mérieux was president of the Institut for 25 years, until 1994.
 
1963
            
Creation of BD Mérieux equally owned by Institut Mérieux and Becton Dickinson.
 
1974 Alain Mérieux takes majority control of the company: BD Mérieux becomes bioMérieux.
 
1986 API Systems (France) acquisition.
 
1988 Vitek acquisition from McDonnel Douglas (U.S.).
 
2001 Organon Teknika Diagnostic acquisition from Akzo Nobel (Netherlands).
 
2003 40th anniversary.
 
2004 Listing of bioMérieux on the stock exchange.
 
2006 Inauguration of the Christophe Mérieux Center, dedicated to molecular biology and microsystems research (Grenoble, France).
Bacterial Barcodes (U.S.) acquisition - DiversiLab™.
 
2007 Biomedics (Spain) acquisition.
BTF (Australia) acquisition.
 
2008 Joint venture with Sysmex (Japan).
Joint venture with Shanghai Kehua Bio-engineering (China).
AB BIODISK (Sweden) acquisition.
AviaraDx (U.S.) acquisition - renamed bioTheranostics, Inc.
 
2009 Strategic partnership with the French Atomic Energy Commission (CEA).
 
2010 Acquisition of Meikang Biotech (China).
Acquisition of Shanghai Zenka Biotechnology (China).
 
2011 Acquisition of AES Laboratoire (France)
Acquisition of ARGENE (France)